JP2025517642A5 - - Google Patents
Info
- Publication number
- JP2025517642A5 JP2025517642A5 JP2024565273A JP2024565273A JP2025517642A5 JP 2025517642 A5 JP2025517642 A5 JP 2025517642A5 JP 2024565273 A JP2024565273 A JP 2024565273A JP 2024565273 A JP2024565273 A JP 2024565273A JP 2025517642 A5 JP2025517642 A5 JP 2025517642A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- alkyl
- group
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263339253P | 2022-05-06 | 2022-05-06 | |
| US63/339,253 | 2022-05-06 | ||
| US202263398783P | 2022-08-17 | 2022-08-17 | |
| US63/398,783 | 2022-08-17 | ||
| US202263429862P | 2022-12-02 | 2022-12-02 | |
| US63/429,862 | 2022-12-02 | ||
| US202363449756P | 2023-03-03 | 2023-03-03 | |
| US63/449,756 | 2023-03-03 | ||
| US202363454545P | 2023-03-24 | 2023-03-24 | |
| US63/454,545 | 2023-03-24 | ||
| US202363457997P | 2023-04-07 | 2023-04-07 | |
| US63/457,997 | 2023-04-07 | ||
| PCT/US2023/021010 WO2023215482A1 (en) | 2022-05-06 | 2023-05-04 | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517642A JP2025517642A (ja) | 2025-06-10 |
| JP2025517642A5 true JP2025517642A5 (enExample) | 2026-05-07 |
Family
ID=86688472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565273A Pending JP2025517642A (ja) | 2022-05-06 | 2023-05-04 | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240238423A9 (enExample) |
| EP (1) | EP4519259A1 (enExample) |
| JP (1) | JP2025517642A (enExample) |
| KR (1) | KR20250008772A (enExample) |
| CN (1) | CN119343345A (enExample) |
| AU (1) | AU2023264018A1 (enExample) |
| CA (1) | CA3251489A1 (enExample) |
| CL (1) | CL2024003362A1 (enExample) |
| IL (1) | IL316465A (enExample) |
| MX (1) | MX2024013537A (enExample) |
| PE (1) | PE20250007A1 (enExample) |
| TW (1) | TW202400589A (enExample) |
| WO (1) | WO2023215482A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202527930A (zh) * | 2023-11-07 | 2025-07-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| TW202535872A (zh) * | 2023-11-07 | 2025-09-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2025101575A1 (en) * | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| WO2025130875A1 (zh) * | 2023-12-18 | 2025-06-26 | 南京瑞初医药有限公司 | 氮杂环化合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| CN113660937A (zh) | 2019-02-08 | 2021-11-16 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| AU2020310147A1 (en) | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| CN112707900B (zh) | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| US12441722B2 (en) | 2020-01-15 | 2025-10-14 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| US20230167105A1 (en) | 2020-04-28 | 2023-06-01 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| US20250197387A1 (en) | 2021-09-17 | 2025-06-19 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
| EP4431511A4 (en) * | 2021-11-09 | 2025-10-15 | Hangzhou Glubio Pharmaceutical Co Ltd | WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE |
-
2023
- 2023-05-04 EP EP23728483.1A patent/EP4519259A1/en active Pending
- 2023-05-04 AU AU2023264018A patent/AU2023264018A1/en active Pending
- 2023-05-04 US US18/143,454 patent/US20240238423A9/en active Pending
- 2023-05-04 CA CA3251489A patent/CA3251489A1/en active Pending
- 2023-05-04 JP JP2024565273A patent/JP2025517642A/ja active Pending
- 2023-05-04 CN CN202380046254.4A patent/CN119343345A/zh active Pending
- 2023-05-04 KR KR1020247040564A patent/KR20250008772A/ko active Pending
- 2023-05-04 IL IL316465A patent/IL316465A/en unknown
- 2023-05-04 WO PCT/US2023/021010 patent/WO2023215482A1/en not_active Ceased
- 2023-05-04 TW TW112116645A patent/TW202400589A/zh unknown
- 2023-05-04 PE PE2024002436A patent/PE20250007A1/es unknown
-
2024
- 2024-10-31 MX MX2024013537A patent/MX2024013537A/es unknown
- 2024-11-04 CL CL2024003362A patent/CL2024003362A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025517642A5 (enExample) | ||
| JP2025516358A5 (enExample) | ||
| JP7326622B2 (ja) | Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用 | |
| AU2022203611A1 (en) | Spray dry formulations | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| AU2014205483B2 (en) | Non-selective kinase inhibitors | |
| JP2019163324A (ja) | Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置 | |
| JP2011514363A5 (enExample) | ||
| JP6824906B2 (ja) | 併用療法 | |
| AU2020319058A1 (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| JP2003521509A (ja) | 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤 | |
| WO2005025574A2 (en) | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | |
| JP2025516359A5 (enExample) | ||
| EP4114830A1 (en) | Heterobifunctional molecules as tead inhibitors | |
| WO2017189893A1 (en) | 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases | |
| US20220227758A1 (en) | Imidazopyridine compound as irak4 inhibitor | |
| CA3201657A1 (en) | Combination therapies for the treatment of cancer | |
| EP3453393A1 (en) | Novel quinazolinone derivatives inhibiting pi3k and pharmaceutical composition containing same | |
| JP2020528877A (ja) | 新規化合物及びそれを有効成分として含有する、線維症または非アルコール性脂肪肝炎の予防、改善または治療用組成物 | |
| KR20110097907A (ko) | 치유적 치료를 위한 ｈｓｐ90 억제제 | |
| CN114404415A (zh) | 吲唑类化合物用于治疗银屑病的用途 | |
| WO2020151749A1 (zh) | 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 | |
| JP2025523057A (ja) | がん処置における使用のためのｃｂｌ－ｂ阻害剤及び抗ｐｄ１／抗ｐｄ－ｌ１ | |
| JP2017504638A (ja) | 重水素化キナゾリノン化合物及び該化合物を含む薬物組成物 | |
| JP2022552019A5 (enExample) |